BioTelemetry, Inc. (NASDAQ:BEAT) – Research analysts at Dougherty & Co reduced their FY2017 earnings per share (EPS) estimates for shares of BioTelemetry in a report released on Sunday. Dougherty & Co analyst G. Mannheimer now forecasts that the medical research company will post earnings per share of $0.84 for the year, down from their prior estimate of $0.99. Dougherty & Co currently has a “Buy” rating and a $40.00 target price on the stock. Dougherty & Co also issued estimates for BioTelemetry’s Q4 2017 earnings at $0.29 EPS.

BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Tuesday, November 7th. The medical research company reported $0.16 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.25 by ($0.09). BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The company had revenue of $81.02 million during the quarter, compared to the consensus estimate of $82.10 million. During the same period in the previous year, the firm posted $0.21 EPS. The business’s quarterly revenue was up 52.7% compared to the same quarter last year. TRADEMARK VIOLATION NOTICE: This piece was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://theolympiareport.com/2017/11/17/dougherty-co-equities-analysts-decrease-earnings-estimates-for-biotelemetry-inc-beat.html.

Other research analysts have also issued research reports about the stock. SunTrust Banks, Inc. initiated coverage on shares of BioTelemetry in a research note on Monday, October 23rd. They issued a “buy” rating and a $41.00 price target on the stock. Sidoti reaffirmed a “buy” rating and issued a $49.00 price target (up previously from $42.00) on shares of BioTelemetry in a research note on Thursday, August 10th. BidaskClub lowered shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Raymond James Financial, Inc. initiated coverage on shares of BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 price objective on the stock. Finally, Off Wall Street initiated coverage on shares of BioTelemetry in a report on Friday, September 15th. They issued a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. BioTelemetry currently has a consensus rating of “Buy” and a consensus target price of $42.86.

Shares of BioTelemetry (NASDAQ:BEAT) traded up $1.10 on Wednesday, reaching $25.25. 650,900 shares of the company’s stock were exchanged, compared to its average volume of 476,483. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60. BioTelemetry has a 1 year low of $18.60 and a 1 year high of $39.20. The company has a market capitalization of $782.66, a price-to-earnings ratio of 33.08, a P/E/G ratio of 1.51 and a beta of 0.58.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Alps Advisors Inc. increased its holdings in BioTelemetry by 0.3% during the second quarter. Alps Advisors Inc. now owns 17,867 shares of the medical research company’s stock worth $598,000 after buying an additional 46 shares during the last quarter. Pinebridge Investments L.P. increased its holdings in BioTelemetry by 2.0% during the second quarter. Pinebridge Investments L.P. now owns 3,775 shares of the medical research company’s stock worth $126,000 after buying an additional 75 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in BioTelemetry by 0.9% during the second quarter. Louisiana State Employees Retirement System now owns 11,700 shares of the medical research company’s stock worth $391,000 after buying an additional 100 shares during the last quarter. Arizona State Retirement System increased its holdings in BioTelemetry by 0.7% during the second quarter. Arizona State Retirement System now owns 14,900 shares of the medical research company’s stock worth $498,000 after buying an additional 100 shares during the last quarter. Finally, Renaissance Group LLC increased its holdings in BioTelemetry by 2.5% during the second quarter. Renaissance Group LLC now owns 12,405 shares of the medical research company’s stock worth $415,000 after buying an additional 301 shares during the last quarter. Institutional investors and hedge funds own 77.87% of the company’s stock.

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.